Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting

Journal of Electrocardiology

Volumn 46, Issue 1, 2013, Pages 45-50

  Han, Seol Young ^a   Palmeri, Sebastian T ^b   Broderick, Samuel H ^c   Hasselblad, Vic ^c   Rendall, Dave ^c   Stevens, Scott ^d   Tenaglia, Alan ^e   Velazquez, Eric ^c   Whellan, David ^f   Wagner, Galen ^c   Heitner, John F ^a  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d INTERMOUNTAIN MEDICAL CENTER   (United States)

^e Scottsdale Cardiovascular Center   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; INR; Stroke prevention and time in therapeutic range; VKA; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMMUNITY CARE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; FEMALE; HEART VALVE DISEASES; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 84872130330     PISSN: 00220736     EISSN: 15328430     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2012.08.011     Document Type: Article

References (44)

1. M.C. Fang, R.S. Stafford, and J.N. Ruskin National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation Arch Intern Med 164 2004 55
2. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370
3. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke. The Framingham Study Stroke 22 1991 983
4. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study Arch Intern Med 147 1987 1561
5. D.A. Dulli, H. Stanko, and R.L. Levine Atrial fibrillation is associated with severe acute ischemic stroke Neuroepidemiology 22 2003 118
6. H.J. Lin Stroke severity in atrial fibrillation Stroke 27 1996 1760
7. M.N. Diringer, D.F. Edwards, and D.T. Mattson Predictors of acute hospital costs for treatment of ischemic stroke in an academic center Stroke 30 1999 724
8. R.G. Hart, O. Benavente, and R. McBride Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-Analysis Ann Intern Med 131 1999 492
9. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449
10. J. Ansell, J. Hirsh, and L. Poller The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 Suppl. 3 2004 204S
11. M.W. Reynolds, K. Fahrbach, and O. Hauch Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis Chest 126 2004 1938
12. E.M. Hylek, A.S. Go, and Y. Chang Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019
13. E.M. Hylek, and D.E. Singer Risk factors for intracranial hemorrhage in outpatients taking warfarin Ann Intern Med 120 1994 897
14. Y. Wan, C. Heneghan, P. Rafael, N. Roberts, J. Hollowell, and P. Glasziou Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 2008 84
15. C. Van Walraven, A. Jennings, and N. Oake Effect of study setting on anticoagulation control: a systematic review and metaregression Chest 129 2006 1155
16. R.J. Beyth, L. Quinn, and C.S. Landefeld A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial Ann Intern Med 133 2000 687
17. A.M. Errichetti, A. Holden, and J. Ansell Management of oral anticoagulant therapy: experience with an anticoagulation clinic Arch Intern Med 144 1984 1966
18. S.J. Wilson, P.S. Wells, and M.J. Kovacs Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial CMAJ 169 4 2003 293
19. S.J. Connolly, J. Pogue, J. Eikelboom for ACTIVE W Investigators Benefit of oral anticoagulant over antiplatelet therapy in AF depends on the quality of the INR control achieved as measured by time in therapeutic range Circulation 118 2008 2029
20. L.B. Goldstein, A.J. Bonito, and D.B. Matchar US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: design, service availability, and common practices Stroke 26 1995 1605
21. F.R. Rosendaal, S.C. Cannegieter, F.J. van der Meer, and E. Briet A method to determine the optimal intensity of oral anticoagulant therapy Thromb Haemost 69 1993 236
22. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation JAMA 285 2001 2864
23. D.A. Cios, W.L. Baker, and S.D. Sander Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-Analysis Am J Health Syst Pharm 66 10 2009 916
24. W.L. Baker, D.A. Cios, S.D. Sander, and C.I. Coleman Meta-Analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 2009 244
25. D.A. Fitzmaurice, E.T. Murray, and D. McCahon Self-management of oral anticoagulation: randomised trial BMJ 331 2005 1057
26. T. Holm, J.F. Lassen, and S.E. Husted A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy J Intern Med 252 2002 322
27. G.W. Albers, H.C. Diener, and L. Frison SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial JAMA 293 2005 690
28. F. Pérez Gómez, E. Alegría, and J. Berjón NASPEAF Investigator. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study J Am Coll Cardiol 44 2004 1557
29. S.B. Olsson Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691
30. S. Connolly, J. Pogue, and R. Hart Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903
31. G. Dolan, L.A. Smith, and S. Collins Effect of setting, monitoring, intensity and patient experience on anticoagulation control: a systematic review and meta- analysis of the literature Curr Med Res Opin 24 2008 1459
32. H.D. White, M. Gruber, and J. Feyzi Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V Arch Intern Med 167 2007 239
33. M. Jones, P. McEwan, C. Morgan, J.R. Peters, J. Goodfellow, and C.J. Currie Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population Heart 91 2005 472
34. T.I. Khan, F. Kamali, and P. Kesteven The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation Br J Haematol 126 2004 557
35. Y.-K. Kim, R. Nieuwlaat, and S.J. Connolly Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study J Thromb Haemost 8 2010 101
36. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139
37. R. Nieuwlaat, L. Barker, and Y.K. Kim Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients Thromb Res 125 2010 e128
38. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883
39. C.B. Granger, J.H. Alexander, and J.J.V. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Eng J Med 365 2011 981
40. International Warfarin Pharmacogenetics Consortium: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753
41. Y. Caraco, S. Blotnick, and M. Muszkat CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safetyof anticoagulation: a prospective randomized controlled study Clin Pharmacol Ther 83 2008 460
42. J.L. Anderson, D. Horne, and S.M. Stevens A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) Circulation 125 2012 1997
43. S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circulation 123 2011 2562e70
44. J. Ansell, J. Hirsh, and J. Dalen Managing oral anticoagulant therapy Chest 119 2001 S22